Plasma

In 2006, GSABC negotiated a new agreement with Octapharma that brings GSABC members the best prices in the marketplace.  As a result of GSABC’s negotiations with Octapharma, the price for recovered plasma rose significantly in 2006, GSABC has had the price leading plasma contract for the past five years.  Consequently, other fractionators not associated with GSABC have been forced to follow our lead by raising their prices, which benefits all members of America’s Blood Centers.

We also added a dedicated staff person, subsidized by Octapharma, to serve as a liaison between participating member centers and the global plasma fractionation company. 

Who is Octapharma?

Octapharma is an independent private company, based in Lachen, Switzerland, with a high degree of flexibility and specialization and an exclusive focus on human plasma products.  Since its foundation in 1983, Octapharma has become on of the key players in the European plasma market and is active in over 70 countries around the world.  Today, the company has more than 1482 employees in 27 countries, and is continuously expanding.  The company has a solid financial background as demonstrated by year on year growth.  Octapharma’s healthy financial situation enables us to heavily invest in the safety and Research & Development of plasma products.

Octapharma offers a wide range of plasma products and services, including:

• Sales of finished plasma derivatives.  All Octapharma products are developed and manufactured by the company.  Plasma for these products is sources from Austria, Germany, Sweden and the United States only.
• Support for self-sufficiency partners.  Octapharma supports countries/organizations who practice self sufficiency to meet their need for plasma products and/or Fresh Frozen Plasma for transfusion (FFP): Plasma from their own region is then shipped to Octapharma and the resulting products are then returned to the country/organization of origin without any mixing with plasma sourced fro other areas.  As Octapharma achieves exceptionally high yields of products from each liter of valuable human plasma, we are an ideal partner for countries seeking to achieve self-sufficiency with limited plasma or economic resources.
• Technology transfer.  Octapharma is internationally recognized for its know-how and skills in the area of plant construction & management, plasma fractionation and yield enhancement.  As such, the company offers technology transfer and licensing to reliable partners throughout the world.  Since 1998, Octapharma has developed agreements with 16 partners in 16 countries who apply Octapharma technology for their own plasma product production.  Technology transfer includes full “turn-key” solutions as well as specific technology licensing.